Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.

NCT00321737 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00321737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00321737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
May 31, 2007
Enrollment
445 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

esophagitis, peptic, esophagitis, reflux